» Articles » PMID: 38706633

Context Base Editing for Splice Correction of IVSI-110 β-thalassemia

Abstract

β-Thalassemia is brought about by defective β-globin (HBB [hemoglobin subunit β]) formation and, in severe cases, requires regular blood transfusion and iron chelation for survival. Genome editing of hematopoietic stem cells allows correction of underlying mutations as curative therapy. As potentially safer alternatives to double-strand-break-based editors, base editors (BEs) catalyze base transitions for precision editing of DNA target sites, prompting us to reclone and evaluate two recently published adenine BEs (ABEs; SpRY and SpG) with relaxed protospacer adjacent motif requirements for their ability to correct the common splice mutation. Nucleofection of ABE components as RNA into patient-derived CD34 cells achieved up to 90% editing of upstream sequence elements critical for aberrant splicing, allowing full characterization of the on-target base-editing profile of each ABE and the detection of differences in on-target insertions and deletions. In addition, this study identifies opposing effects on splice correction for two neighboring context bases, establishes the frequency distribution of multiple BE editing events in the editing window, and shows high-efficiency functional correction of for our ABEs, including at the levels of RNA, protein, and erythroid differentiation.

Citing Articles

Editing of homologous globin genes by nickase-deficient base editor mitigates large intergenic deletions in HSPCs.

George A, Sadanandan P, Ravi N, Vaishnavi B, Marepally S, Thangavel S Mol Ther Nucleic Acids. 2024; 35(4):102347.

PMID: 39469667 PMC: 11513543. DOI: 10.1016/j.omtn.2024.102347.


Therapeutic Gene Editing for Hemoglobinopathies.

Testa U, Leone G, Cappellini M Mediterr J Hematol Infect Dis. 2024; 16(1):e2024068.

PMID: 39258178 PMC: 11385271. DOI: 10.4084/MJHID.2024.068.


Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β-Thalassemia Mouse Model.

Lu D, Gong X, Guo X, Cai Q, Chen Y, Zhu Y Hum Gene Ther. 2024; 35(19-20):825-837.

PMID: 39078325 PMC: 11514127. DOI: 10.1089/hum.2023.202.


Precision genome editing offers hope for treatment of β-thalassemia and other genetic disorders.

Abbas Z, Rahman A, Aslam B, Aftab S, Feng C, Baloch Z Mol Ther Nucleic Acids. 2024; 35(2):102204.

PMID: 38800557 PMC: 11126523. DOI: 10.1016/j.omtn.2024.102204.

References
1.
Papaioannou N, Patsali P, Naiisseh B, Papasavva P, Koniali L, Kurita R . High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on mRNA synthesis. Front Genome Ed. 2023; 5:1141618. PMC: 10030607. DOI: 10.3389/fgeed.2023.1141618. View

2.
Patsali P, Papasavva P, Stephanou C, Christou S, Sitarou M, Antoniou M . Short-hairpin RNA against aberrant mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cells. Haematologica. 2018; 103(9):e419-e423. PMC: 6119153. DOI: 10.3324/haematol.2018.189357. View

3.
Patel C, Ghiselli G . Hinderin, a five-domains protein including coiled-coil motifs that binds to SMC3. BMC Cell Biol. 2005; 6(1):3. PMC: 547899. DOI: 10.1186/1471-2121-6-3. View

4.
Doench J, Fusi N, Sullender M, Hegde M, Vaimberg E, Donovan K . Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):184-191. PMC: 4744125. DOI: 10.1038/nbt.3437. View

5.
Patsali P, Mussolino C, Ladas P, Floga A, Kolnagou A, Christou S . The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements. J Clin Med. 2019; 8(11). PMC: 6912506. DOI: 10.3390/jcm8111959. View